| Lee AV, Gooch JL, Oesterreich S, Guler RL, Yee D. IGF-I induced degradation of insulin receptor substrate-1 is mediated by the 26S proteasome and blocked by phophatidylinostiol 3'-kinase inhibition. Mol Cell Biol 2000; 20: 1489-1496. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002; 62:4491-4498. Schmitz KH, Ahmed RL, Yee D. Effects of a 9-month strength training intervention on insulin, insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-1, and IGFBP-3 in 30-50-year-old women. Cancer Epidemiol Biomarkers Prev 2002; 11:1597-1604. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 2003; 63:627-635. Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 2004; 279:5017-5024. Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB, Polunovsky VA. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004; 5:553-563. Hoang CD, Zhang X, Scott PD, Guillaume TJ, Maddaus MA, Yee D, Kratzke RA. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: Association with distinct malignant phenotypes. Cancer Res 2004; 64:7479-7485. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, Garwood M. Neoadjuvant chemotherapy of locally advanced breast cancer: Predicting response with in vivo (1)H MR spectroscopy -- a pilot study at 4 T. Radiology 2004; 233:424-431. Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res. 2006; 66:2391-402. Kirstein MN, Brundage RC, Elmquist WF, Remmel RP, Marker PH, Guire DE, Yee D. Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. Breast Cancer Res Treat. 2006; 96:217-25. Haddad T, Yee D. Targeting the insulin-like growth factor axis as a cancer therapy. Future Oncol. 2006; 2:101-10. Ibrahim YH, Byron SA, Cui X, Lee AV, Yee D. Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2. Mol Cancer Res. 2008; 6:1491-1498. Zhang H, Yee D, Wang C. Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives. Nanomed. 2008; 3: 83-91. Lange CA, Yee D. Progesterone and breast cancer. Womens Health (Lond Engl). 2008; 4: 151-62. PMID: 19072517 Zhang H, Sachdev D, Wang C, Hubel A, Gaillard-Kelly M, Yee D. Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells. Breast Cancer Res Treat. 2009; 114:277-85. PMID: 18418709 Zeng X, Sachdev D, Zhang H, Gaillard-Kelly M, Yee D. Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo. Clin Cancer Res. 2009 Apr 15;15(8):2840-9. Epub 2009 Apr 7.PMID: 19351773 Zhang H, Zeng X, Li Q, Gaillard-Kelly M, Wagner CR, Yee D. Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore. Br J Cancer. 2009 Jul 7;101(1):71-9. Epub 2009 Jun 2.PMID: 19491901 Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D. The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene. 2010 Jan 14;29(2):251-62. Epub 2009 Oct 19.PMID: 19838209 Blaes AH, Gaillard P, Peterson BA, Yee D, Virnig B. Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Res Treat. 2010 Jul;122(2):585-90. Epub 2010 Jan 8.PMID: 20058065 Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene. 2010 Apr 29;29(17):2517-27. Epub 2010 Feb 15.PMID: 20154728 Yee D. Adaptor proteins as targets for cancer prevention. Cancer Prev Res (Phila). 2010 Mar;3(3):263-5. Epub 2010 Feb 23.PMID: 20179300 Yee D. How to train your biomarker. Clin Cancer Res. 2010 Jun 15;16(12):3091-3. Epub 2010 Jun 8.PMID: 20530694 Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010 Jul-Aug;60(4):207-21. Epub 2010 Jun 16.PMID: 20554718 Hui SK, Khalil A, Zhang Y, Coghill K, Le C, Dusenbery K, Froelich J, Yee D, Downs L. Longitudinal assessment of bone loss from diagnostic computed tomography scans in gynecologic cancer patients treated with chemotherapy and radiation. Am J Obstet Gynecol. 2010 Oct;203(4):353.e1-7. Epub 2010 Aug 3.PMID: 20684943 Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF Pathway Regulates ER{alpha} through a S6K1-Dependent Mechanism in Breast Cancer Cells. Mol Endocrinol. 2011 Mar;25(3):516-28. Potter DA, Yee D, Guo Z, Rodriguez M. Should diabetic women with breast cancer have their own intervention studies? Endocr Relat Cancer. 2012 Feb 13;19(1):C13-7. Hui SK, Fairchild GR, Kidder LS, Sharma M, Bhattacharya M, Jackson S, Le C, Yee D. Skeletal remodeling following clinically relevant radiation-induced bone damage treated with zoledronic acid. Calcif Tissue Int. 2012 Jan;90(1):40-9. |
